![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ONL Secures Orphan Designation for Retinal Detachment Candidate
ONL Secures Orphan Designation for Retinal Detachment Candidate
Ann Arbor, Mich.-based ONL Therapeutics has won orphan drug designation from the FDA for ONL 1204, a candidate to treat retinal detachment.
ONL 1204 is designed to protect retinal cells from death resulting from disease or conditions.
As a result of the designation, ONL may gain certain incentives, including tax credits and a seven-year period of market exclusivity.
Upcoming Events
-
21Oct